Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Studie zur Bewertung der Sicherheit und Verträglichkeit steigender Fostamatinib-Dosen bei Patienten mit stabiler Sichelzellanämie

4. November 2026 aktualisiert von: National Heart, Lung, and Blood Institute (NHLBI)

Eine Phase-I-Studie zur Bewertung der Sicherheit und Verträglichkeit steigender Fostamatinib-Dosen bei Patienten mit stabiler Sichelzellanämie

Background:

Sickle cell disease (SCD) is a genetic disease that causes the body to produce abnormal ("sickled") red blood cells. SCD can cause anemia and life-threatening complications in the lungs, heart, kidney, and nerves. People with SCD are also at increased risk of forming blood clots in the veins and lungs, but the standard treatments for these clots can cause increased bleeding in people with SCD. Better treatments are needed.

Objective:

To test a drug (fostamatinib) in people with SCD.

Eligibility:

People aged 18 to 65 with SCD.

Design:

Participants will have 6 clinic visits over 12 weeks. Each visit will be 2 to 3 hours.

Participants will be screened. They will have a physical exam with blood tests. They will tell the researchers about the medications they take.

Fostamatinib is a tablet taken by mouth. Participants will take the drug at home, twice a day, for up to 6 weeks.

Participants will have a clinic visit every 2 weeks while they are taking the drug. At each visit they will have a physical exam with blood tests. They will talk about any side effects the drug may be causing. If they are tolerating the drug well after the first 2 weeks, they may begin taking a higher dose.

Participants will have a final visit 4 weeks after they stop taking the drug. They will have a physical exam and blood tests; they will be checked for any side effects of the drug.

Studienübersicht

Detaillierte Beschreibung

Study Description:

The overall objective of this study is to assess the clinical safety and tolerability of fostamatinib in subjects with stable sickle cell disease (SCD). Subjects enrolled in cohort 1 will receive fostamatinib 100 mg orally twice daily (BID) for 2 weeks then escalate to 150 mg orally BID for an additional four weeks. Subjects enrolled in cohort 2 will receive fostamatinib 100 mg orally once daily (QD) for 2 weeks then escalate to 150 mg orally QD for an additional four weeks. Cohort 2 will allow the subjects from cohort 1 the option to re-enroll to undergo the QD dosing regimen. Throughout the course of the study subjects will be monitored for signs and symptoms of adverse events. The effect of fostamatinib on laboratory biomarkers of inflammatory activity and red blood cell metabolism will be studied at specified timepoints.

Objectives:

Primary Objective:

To assess the clinical safety and tolerability of fostamatinib, a tyrosine kinase inhibitor with demonstrated activity against spleen tyrosine kinase (Syk), in subjects with stable SCD.

Secondary Objectives:

To assess the pharmacokinetics of fostamatinib in SCD and correlate drug exposure to effects on neutrophil, platelet function, and red cell metabolism to evaluate for anti-sickling and anti-inflammatory effects (Cohort 1).

To evaluate anti-sickling and anti-inflammatory effects of fostamatinib in SCD via neutrophil function and red cell metabolism (Cohort 2).

Exploratory Objectives:

To gain insight into the exposure response and mechanistic effects of fostamatinib mediated Syk inhibition on intracellular signaling.

Compare anti-sickling and anti-inflammatory effects of fostamatinib between 2 dose regimens.

Endpoints:

Primary Endpoint:

  • To evaluate the safety and tolerability of fostamatinib as assessed by:

    --frequency and severity of adverse events (AEs) from Baseline to Day 70

  • Safety endpoints, including:

    • the type, incidence, severity, and relationship to study treatment of AEs and serious adverse events (SAEs) from Baseline to Day 70
    • number of discontinuations due to AEs; from Baseline to Day 70
    • results of clinical laboratory tests over time and change from baseline (e.g., serum chemistry, liver function test, hematology, coagulation)

Secondary Endpoints:

  • Neutrophil activation and NETosis at regular time intervals (baseline, days 14, 43, and end of study) on fostamatinib and change from baseline.
  • Percentage of sickled cells and time to 50% sickling (t50) under normal and hypoxic ex vivo conditions at regular time intervals (baseline, days 14, 43, and end of study) on fostamatinib and change from baseline.
  • Evaluate anti-sickling effects of fostamatinib through measures of red blood cell (RBC) membrane band3 tyrosine phosphorylation, RBC deformability, anti-sickling kinetics and oxygen affinity (p50) at regular time intervals (baseline, days 14, 43, and end of study) on fostamatinib and change from baseline.
  • Change from baseline in intracellular reactive oxidative species (ROS) in RBCs at different doses of fostamatinib at regular time intervals (baseline, days 14, 43 and end of study).
  • Determine peak R406 levels and assess correlation of R406 exposure with inhibition of NETosis and its effect on red blood cell membrane band 3 tyrosine phosphorylation and sickling kinetics at baseline, 1 hr, 2 hrs, 4 hrs, and 8 hrs post dosing on 100 mg BID and 150 mg BID (Cohort 1)

Exploratory Endpoints:

  • Proteomic, metabolomic and lipidomic studies to evaluate the effect of fostamatinib on RBCs and monocytes at regular time intervals (baseline, days 14, 43 and end of study).
  • Studies of extracellular vesicles (EVs) at regular time intervals (baseline, days 14, 43 and end of study).
  • Measures of neutrophil activation and neutrophil extracellular trap (NET) formation at baseline and following agonistactivation Z
  • Compare fostamatinib at different doses on secondary and exploratory endpoints by comparing data from subjects who have received both dose levels.

Studientyp

Interventionell

Einschreibung (Geschätzt)

35

Phase

  • Phase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

    • Maryland
      • Bethesda, Maryland, Vereinigte Staaten, 20892
        • Rekrutierung
        • National Institutes of Health Clinical Center
        • Kontakt:
          • NIH Clinical Center Office of Patient Recruitment (OPR)
          • Telefonnummer: 800-411-1222
          • E-Mail: prpl@cc.nih.gov

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 65 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

  • INCLUSION CRITERIA:

Subjects will enroll onto the study and undergo screening. Subjects who do not meet any of the following criteria during screening will not receive the study intervention but will be counted toward study accrual. Screen failures may be rescreened at a later time. In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  1. Have provided signed written informed consent prior to performing any study procedure, including screening procedures.

  2. Age between 18-65 years

  3. Unequivocal diagnosis of SCA (HbSS or HbSBeta^0) confirmed by hemoglobin electrophoresis performed on patients at least 60 days after a blood transfusion if previously transfused.

  4. No transfusion in the 60 days prior to signing consent, or absence of Hb A on hemoglobin analysis (by high-performance liquid chromatography; HPLC)

  5. Have adequate organ function, as defined by:

    1. Serum aspartate aminotransferase (AST) <=1.5 x Upper Limit of Normal (ULN) (unless the increased AST is assessed by the Investigator as due to hemolysis) and alanine aminotransferase (ALT) <=1.5 x ULN.
    2. Absolute neutrophil count >=1.5 x 10^9/L.
    3. Hemoglobin >= 7 g/dL
    4. Platelet count >=100 x 10^9/L.
  6. If on hydroxyurea, participant must have been on stable dose of hydroxyurea (defined as a stable dose for at least 3 months and inclusive of dose modifications for hematological toxicity per PI discretion) prior to signing consent.

  7. For women of reproductive potential, have a negative serum pregnancy test during the screening period. Women of reproductive potential are defined as sexually mature women who have not undergone a hysterectomy, bilateral oophorectomy, or tubal occlusion; or who have not been naturally postmenopausal (i.e., who have not menstruated at all for at least the preceding 1 year prior to signing informed consent unrelated to hormonal contraception).

  8. For women of reproductive potential as well as men and their partners who are women of reproductive potential, be abstinent as part of their usual lifestyle, or agree to use 2 effective forms of contraception from the time of giving informed consent, during the study, and for 28 days (both men and women) following the last dose of study treatment. An effective form of contraception is defined as hormonal oral contraceptives, injectables, patches, intrauterine or subdermal contraceptive implants, and barrier methods.

  9. Be willing to comply with all study procedures for the duration of the study.

  10. Must be able to provide consent

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Pain crisis requiring parenteral treatment within 14 days of signing consent.

  2. Have a significant medical condition that confers an unacceptable risk to participating in the study, and/or that could confound the interpretation of the study data. Such significant medical conditions include, but are not limited to the following:

    1. History of neutropenia (benign ethnic neutropenia and/or acquired neutropenia related to drug suppression by hydroxyurea and/or cyclic hematopoiesis are permitted).
    2. History of posterior reversible encephalopathy syndrome (PRES)
    3. History of poorly controlled hypertension (defined as systolic blood pressure >=130 mmHg or average diastolic blood pressure >=90 mmHg based on an average of 3 blood pressure readings despite adequate antihypertensive therapy) unless controlled for >90 days prior to enrollment.
    4. Active viral infection as evidenced by testing positive for hepatitis B surface antigen or hepatitis C virus (HCV) antibody (ab) with signs of active hepatitis B or C virus infection. If the subject is positive for HCV Ab, a reverse transcriptase-polymerase chain reaction test will be conducted. Subjects with hepatitis C may be rescreened after receiving appropriate hepatitis C treatment.
    5. History of drug-induced cholestatic hepatitis.
    6. History of any primary malignancy.
    7. Testing positive for human immunodeficiency virus 1 or 2 Ab with evidence for ongoing active infection (i.e., CD 4 count <400/microliter and viral load >100,000 copies/ml) on antiretroviral therapy.
    8. Current or recent history of psychiatric disorder that, in the opinion of the Investigator or Medical Monitor, could compromise the ability of the subject to cooperate with study visits and procedures.
    9. Are currently enrolled in another therapeutic clinical trial involving ongoing therapy with any investigational or marketed product or placebo.
    10. Use of newly approved SCD therapy (L-glutamine or crizanlizumab) is NOT permitted on this study. Subjects who have received newly approved SCD therapy in the 7 days prior to signing consent will be excluded.
    11. Having had a prior bone marrow or stem cell transplant.
    12. Currently pregnant or lactating.
    13. Currently receiving strong inhibitors of CYP3A4/5 that have not been stopped for >=5 days or a time frame equivalent to 5 half-lives (whichever is longer), or strong inducers of CYP3A4 that have not been stopped for >=28 days or a time frame equivalent to 5 half-lives (whichever is longer), prior to signing consent. SCD patients that are receiving treatment with CYP3A4 substrate drugs, some BCRP substrate drugs (eg. rosuvastatin), and some P-glycoprotein substrate drugs (eg. Digoxin) are excluded from the study.
    14. Currently receiving erythropoiesis stimulating agents.
  3. Has received fostamatinib in 3 months prior to signing consent

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Grundlegende Wissenschaft
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Cohort 1: Fostamatinib 100 mg BID - 150 mg BID

Cohort 1: Four participants with sickle cell disease will receive fostamatinib 100 mg orally twice daily for 2 weeks, followed by 150 mg orally twice daily for 4 weeks.

Fostamatinib will be administered orally for 6 weeks. Dosing will begin at 100 mg and increase to 150 mg after 2 weeks. The dosing frequency will be once daily or twice daily, depending on cohort assignment.

Experimental: Cohort 2: Fostamatinib 100 mg QD - 150 mg QD Cohort 2 re-enrollment subgroup

Up to 19 participants with sickle cell disease, including at least 15 treatment-naive participants and up to 4 participants from Cohort 1 who elect to continue under the revised dosing regimen, will receive fostamatinib 100 mg orally once daily for 2 weeks, followed by 150 mg orally once daily for 4 weeks.Up to 4 participants who previously completed Cohort 1 may re-enroll in Cohort 2 after a 3-month washout period. These participants receive the QD regimen and may be compared with their prior BID exposure in an exploratory, hypothesis-generating analysis.

Fostamatinib will be administered orally for 6 weeks. Dosing will begin at 100 mg and increase to 150 mg after 2 weeks. The dosing frequency will be once daily or twice daily, depending on cohort assignment.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Safety and tolerability of fostamatinib
Zeitfenster: From baseline through Day 70 (end-of-study follow-up; approximately 28 days after the final dose)

Assess the frequency, type, severity, and relationship to fostamatinib of adverse events (AEs) and serious adverse events (SAEs); the number of participants who discontinue treatment because of AEs; and changes over time from baseline in clinical laboratory measures, including serum chemistry, liver function, hematology, and coagulation parameters. Specific laboratory measures include hemoglobin, reticulocyte count, bilirubin, lactate dehydrogenase, white blood cell count, absolute neutrophil count, and platelet count.

From baseline through Day 70 (end-of-study follow-up; approximately 28 days after the final dose)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Time to 50% sickling (t50)
Zeitfenster: Baseline, Day 14, Day 43, and Day 70

Measure the time required for 50% of red blood cells to sickle under ex vivo conditions as an indicator of anti-sickling activity.

Baseline, Day 14, Day 43, and Day 70
Percentage of sickled red blood cells
Zeitfenster: Baseline, Day 14, Day 43, and Day 70

Assess the percentage of sickled cells under normal and hypoxic ex vivo conditions and evaluate change from baseline.

Baseline, Day 14, Day 43, and Day 70
Neutrophil activation and NETosis
Zeitfenster: Baseline, Day 14, Day 43, and end of study/Day 70

Measure changes from baseline in neutrophil activation and neutrophil extracellular trap formation during fostamatinib treatment.

Baseline, Day 14, Day 43, and end of study/Day 70
RBC Band 3 tyrosine
Zeitfenster: Baseline, Day 14, Day 43, and Day 70

Evaluate the effect of fostamatinib on tyrosine phosphorylation of the RBC membrane Band 3 protein, a marker related to RBC membrane integrity and sickling biology.

Baseline, Day 14, Day 43, and Day 70
RBC deformability
Zeitfenster: Baseline, Day 14, Day 43, and Day 70

Baseline, Day 14, Day 43, and Day 70

Baseline, Day 14, Day 43, and Day 70
Anti-sickling kinetics
Zeitfenster: Baseline, Day 14, Day 43, and Day 70

Characterize the kinetics of RBC sickling under ex vivo conditions and determine whether fostamatinib alters sickling behavior.

Baseline, Day 14, Day 43, and Day 70
Oxygen affinity of hemoglobin (p50)
Zeitfenster: Baseline, Day 14, Day 43, and Day 70

Measure the oxygen tension at which hemoglobin is 50% saturated to evaluate treatment-related changes in RBC oxygen-binding properties.

Baseline, Day 14, Day 43, and Day 70
Measure the oxygen tension at which hemoglobin is 50% saturated to evaluate treatment-related changes in RBC oxygen-binding properties.
Zeitfenster: Baseline, Day 14, Day 43, and Day 70

Assess change from baseline in intracellular oxidative stress in RBCs at the different fostamatinib dose levels.

Baseline, Day 14, Day 43, and Day 70
R406 exposure and pharmacodynamic effects
Zeitfenster: Cohort 1: baseline, 1, 2, 4, and 8 hours after dosing on Days 0 and 14

Determine peak plasma levels of R406, the active fostamatinib metabolite, and correlate exposure with inhibition of NETosis, Band 3 tyrosine phosphorylation, RBC effects, and sickling kinetics.

Cohort 1: baseline, 1, 2, 4, and 8 hours after dosing on Days 0 and 14
Dose-regimen comparison
Zeitfenster: Across the treatment period and scheduled assessment visits

Exploratorily compare secondary biomarker outcomes between the BID regimen in Cohort 1 and the QD regimen in Cohort 2, including within-participant comparisons for participants who complete both regimens.

Across the treatment period and scheduled assessment visits

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Swee Lay Thein, M.D., National Heart, Lung, and Blood Institute (NHLBI)

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

18. Dezember 2024

Primärer Abschluss (Geschätzt)

14. Mai 2027

Studienabschluss (Geschätzt)

14. Mai 2027

Studienanmeldedaten

Zuerst eingereicht

13. Juni 2023

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

13. Juni 2023

Zuerst gepostet (Tatsächlich)

15. Juni 2023

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

5. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

4. November 2026

Zuletzt verifiziert

29. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren